Aura Biosciences to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Aura Biosciences (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors, has announced its participation in two upcoming investor conferences in March 2025.

CEO Elisabet de los Pinos will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 9:10 a.m. ET. She will also attend the Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, with a fireside chat scheduled for 8:00 a.m. ET.

Live webcasts of both presentations will be available on the "Investors & Media" page under the "Events & Presentations" section of Aura's website. Replays will remain accessible for 90 days following each presentation.

News Market Reaction

-1.22%

1 alert

-1.22% News Effect

On the day this news was published, AURA declined 1.22%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

BOSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences:

• TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025.
  Fireside Chat at 9:10 a.m. ET.
• Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025.
  Fireside Chat at 8:00 a.m. ET.

The live webcasts of both fireside chats will be available on the “Investors & Media” page under the “Events & Presentations” section of the Company’s website at https://ir.aurabiosciences.com/events-and-presentations, where a replay of each webcast will be archived for 90 days following the presentation date.

About Aura Biosciences

Aura Biosciences is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. Our lead candidate, bel-sar (AU-011), is currently in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. Aura Biosciences is headquartered in Boston, MA. Our mission is to grow as an innovative global oncology company that positively transforms the lives of patients.

For more information, visit aurabiosciences.com. Follow us on X (formerly Twitter) @AuraBiosciences and visit us on LinkedIn.

Investor and Media Contact:
Alex Dasalla
Head of Investor Relations and Corporate Communications
IR@aurabiosciences.com

FAQ

When will Aura Biosciences (AURA) present at the TD Cowen Health Care Conference in March 2025?

Aura Biosciences will present at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, with a fireside chat at 9:10 a.m. ET.

What investor conferences is Aura Biosciences (AURA) attending in March 2025?

Aura Biosciences is attending two investor conferences in March 2025: the TD Cowen 45th Annual Health Care Conference on March 4 and the Leerink Partners Global Healthcare Conference on March 11.

How can investors access Aura Biosciences' (AURA) conference presentations in March 2025?

Investors can access live webcasts of Aura's presentations on the company's website at https://ir.aurabiosciences.com/events-and-presentations, where replays will be available for 90 days afterward.

What time is Aura Biosciences' (AURA) presentation at the Leerink Partners Conference in March 2025?

Aura Biosciences will present at the Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, with a fireside chat scheduled for 8:00 a.m. ET.

Who will represent Aura Biosciences (AURA) at the March 2025 investor conferences?

Elisabet de los Pinos, PhD, Chief Executive Officer of Aura Biosciences, will represent the company at both March 2025 investor conferences.